Opens in a new tab or window SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body ...

The average 15.4%-22.9% weight losses across the tirzepatide doses achieved initially in the trial were maintained throughout ...

This implies monthly maintenance doses, which would give it a big leg up on tirzepatide and semaglutide, which require weekly ...

Novo Nordisk said on Friday its weight-loss drug met the main goals of a late-stage trial in patients with a type of fatty ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the weight-loss effects of the two blockbuster slimming jabs ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report), retaining the price ...

Palatin (PTN) has completed enrollment in the study investigating the safety, tolerability, and effectiveness of co-administration of ...